Rivaroxaban — NZ Medication Guide
📋 Reviewed by a Registered Pharmacist NZ — This information is for general educational purposes only and does not replace professional medical advice. Always consult your doctor or pharmacist before starting, stopping, or changing any medication.
What is Rivaroxaban?
Rivaroxaban is a direct oral anticoagulant (DOAC) — a direct factor Xa inhibitor — used for stroke prevention in atrial fibrillation and venous thromboembolism treatment. This medication is funded by Pharmac under Special Authority for AF and VTE.
What is Rivaroxaban Used For?
Rivaroxaban is used for stroke and systemic embolism prevention in non-valvular atrial fibrillation, treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and extended thromboprophylaxis after major orthopaedic surgery.
How Does Rivaroxaban Work?
Rivaroxaban directly and selectively inhibits factor Xa — a critical serine protease in the coagulation cascade. Blocking factor Xa prevents the conversion of prothrombin to thrombin, which is essential for fibrin clot formation. Unlike warfarin, rivaroxaban does not require monitoring of INR.
How to Take Rivaroxaban
Dose depends on indication: for AF stroke prevention — 20 mg once daily with the evening meal; for DVT/PE treatment — 15 mg twice daily with food for 3 weeks, then 20 mg once daily. Taking with food improves absorption and reduces peak-to-trough variation.
Common Side Effects of Rivaroxaban
- Bleeding (any site — minor bruising to major bleeding)
- Nausea
- Elevated liver enzymes
Serious Side Effects — Seek Medical Attention
Contact your doctor or call 111 immediately if you experience any of the following:
- Major bleeding (gastrointestinal, urogenital, intracranial — more serious risk)
- No routine monitoring of anticoagulant effect (unlike warfarin — assess renal function and potential drug interactions)
- Spinal/epidural haematoma (if used near neuraxial anaesthesia — serious)
Drug Interactions
Rivaroxaban may interact with other medicines. Always inform your doctor and pharmacist of all medications you are taking. Key interactions include:
- Strong CYP3A4 and P-gp inhibitors (ketoconazole, ritonavir — increase rivaroxaban levels significantly)
- Strong CYP3A4 and P-gp inducers (rifampicin, carbamazepine, phenytoin — reduce levels — avoid)
- NSAIDs, aspirin, clopidogrel (increased bleeding risk)
- Other anticoagulants and antiplatelets
New Zealand Prescribing Information
Rivaroxaban (10 mg, 15 mg, 20 mg tablets — Xarelto®) is funded by Pharmac under Special Authority for non-valvular AF and VTE. Unlike warfarin, rivaroxaban does not require INR monitoring, provides more predictable anticoagulation, and has fewer food and drug interactions. It should be avoided in severe renal impairment (eGFR <15 mL/min) and is contraindicated with prosthetic heart valves.
Frequently Asked Questions
Do I need blood tests to monitor rivaroxaban?
Unlike warfarin, rivaroxaban does not require routine INR monitoring. However, kidney function (eGFR) and liver function should be checked at baseline and at least annually — rivaroxaban is cleared by the kidneys, and dose adjustment or discontinuation is needed if renal function deteriorates.
What do I do if I miss a dose of rivaroxaban for AF?
For AF (once daily, 20 mg): take the missed dose on the same day as soon as you remember. Do not take two doses on the same day. For the twice-daily VTE regimen: take the missed dose straight away and continue the next dose at the usual time. Contact your anticoagulation service or pharmacist if unsure.
⚠️ Disclaimer: This page is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or a qualified health provider. In New Zealand, medication availability and funding may vary — check with Pharmac or your pharmacist for current information.
Reviewed by a Registered Pharmacist NZ
References & Further Information
The following New Zealand and international resources were used to inform this page: